Inactive Instrument

Sophiris Bio

Equities

SPHS

CA83578Q2099

Sophiris Bio, Inc. Announces Joseph L. Turner Would Not Be Stand for Re-Election at the Annual General Meeting

April 29, 2016 at 04:20 pm EDT

On April 25, 2016, Joseph L. Turner notified Sophiris Bio Inc. that he would not be standing for re-election at the Company's upcoming Annual General Meeting on May 27, 2016 for personal reasons unrelated to a disagreement with the Company. As such, Mr. Turner's term on the Board of Directors will expire effective at the time of the Company's Annual General Meeting.

Latest news about Sophiris Bio

Swiss franc rises to six year high as central bank stands back	21-11-30	RE
Sophiris Bio : Swiss c.bank diverges from peers to stick with ultra-loose monetary course	21-09-23	RE
Transcript : Sophiris Bio, Inc. - Special Call	19-06-19
Transcript : Sophiris Bio, Inc. - Special Call	18-12-17
Sophiris Bio, Inc. Announces Joseph L. Turner Would Not Be Stand for Re-Election at the Annual General Meeting	16-04-29	CI
Sophiris Bio, Inc. Auditor Raises 'Going Concern' Doubt	16-03-28	CI
Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015	16-03-23	CI
Sophiris Bio, Inc. Reports Encouraging Preliminary Data from Phase 2A Proof of Concept Study in Localized Prostate Cancer	16-01-28	CI
Sophiris Bio, Inc. announced that it has received $2.8 million in funding from Aspire Capital Partners, LLC	15-12-30	CI
Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	15-11-16	CI
Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint	15-11-10	CI
Sophiris Bio, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015	15-08-13	CI
Sophiris Bio, Inc. Enrolls First Patients in Phase 2a Proof of Concept Prostate Cancer Study	15-05-26	CI
Sophiris Bio Inc. Announces Unaudited Consolidated Financial Results for the Three Months Ended March 31, 2015	15-05-13	CI
Sophiris Bio, Inc. Announces Unaudited Consolidated Cash Flow Results for the Year Ended December 31, 2014	15-04-27	CI
Sophiris Bio, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014	15-03-10	CI
Sophiris Bio Inc. Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia	14-12-18	CI
Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014	14-11-12	CI
Sophiris Bio Seeks Acquisitions	14-09-16	CI
Sophiris Bio Reports Completion of Enrollment in the 'PLUS-1' Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia	14-09-02	CI
Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014	14-08-07	CI
Sophiris Bio Inc., Sophiris Bio Corp. and Sophiris Bio Holding Corp. Enter $6.0 Million Loan and Security Agreement with Oxford Finance LLC	14-07-07	CI
Sophiris Bio, Inc. announced that it has received $6 million in funding from Oxford Finance LLC.	14-06-30	CI
Sophiris Bio, Inc. announced that it expects to receive $15 million in funding from Aspire Capital Partners, LLC	14-05-15	CI
Sophiris Bio, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014	14-05-13	CI

Chart Sophiris Bio

Duration

Period

More charts

Company Profile

Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer. Topsalysin, a genetically modified recombinant protein, is delivered through ultrasound-guided injection directly into the prostate. This membrane-disrupting protein is selectively activated by enzymatically active prostate specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. This method of administration limits the circulation of the drug in the body. The Company has completed Phase III clinical trials of topsalysin.

Sector

More about the company